Benitec Biopharma Surges 8% as Investors Chase Strong Momentum and Pipeline Promise
Benitec Biopharma surges 8% as investors rally behind its ddRNAi platform targeting OPMD and hepatitis B—market momentum fuels optimism.
- BENITEC BIOPHARMA INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read